FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 337:581-588 August 28, 1997 Number 9 Next

	Full Text PDF Letters Letters Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million.

Methods We identified valvular heart disease in 24 women treated with fenfluramine–phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine–phentermine therapy.

Results Twenty-four women (mean [±SD] age, 44±8 years) were evaluated 12.3±7.1 months after the initiation of fenfluramine–phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease.

Conclusions These cases arouse concern that fenfluramine–phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine–phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.

Source Information

From the Divisions of Cardiovascular Diseases and Internal Medicine (H.M.C., M.D.M., B.S.E.), Preventive and Occupational Medicine, Endocrinology, and Internal Medicine (D.D.H.), Anatomic Pathology (W.D.E.), and Thoracic and Cardiovascular Surgery (H.V.S.), Mayo Clinic and Mayo Foundation, Rochester, Minn.; and the MeritCare Medical Center, Heart Services, Fargo, N.D. (J.L.C.).

Address reprint requests to Dr. Connolly at the Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

Full Text of this Article

Related Letters:

Valvular Heart Disease Associated with Fenfluramine–Phentermine
Thompson P. D., Kurz X., Van Ermen A., Rasmussen S., Corya B. C., Glassman R. D., Redmon B., Raatz S., Bantle J. P., Wolff F. W., Spitzer W. O., Marshall E. M., Connolly H. M., McGoon M. D., Curfman G. D.
Extract | Full Text  
N Engl J Med 1997; 337:1772-1776, Dec 11, 1997. Correspondence

Further Cases of Valvular Heart Disease Associated with Fenfluramine–Phentermine
Graham D. J., Green L.
Extract | Full Text  
N Engl J Med 1997; 337:635, Aug 28, 1997. Correspondence

Endocardial Fibrosis Associated with Fenfluramine–Phentermine
Fowles R. E., Cloward T. V., Yowell R. L.
Extract | Full Text  
N Engl J Med 1998; 338:1316-1317, Apr 30, 1998. Correspondence

Fetal DNA and Cells in Women with Systemic Sclerosis
Connolly M. K., McCalmont T. H., Daniell H. W., Artlett C. M., Smith J. B., Jimenez S. A.
Extract | Full Text  
N Engl J Med 1998; 339:771-772, Sep 10, 1998. Correspondence

This article has been cited by other articles:

• 2006 WRITING COMMITTEE MEMBERS, , Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e523-e661 [Full Text]  
• Kars, M, Pereira, A M, Bax, J J, Romijn, J A (2008). Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159: 363-367 [Abstract] [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Nishimura, R. A., Carabello, B. A., Faxon, D. P., Freed, M. D., Lytle, B. W., O'Gara, P. T., O'Rourke, R. A., Shah, P. M. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1-e142 [Full Text]  
• Kars, M., Delgado, V., Holman, E. R., Feelders, R. A., Smit, J. W. A., Romijn, J. A., Bax, J. J., Pereira, A. M. (2008). Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma. J. Clin. Endocrinol. Metab. 93: 3348-3356 [Abstract] [Full Text]  
• Townsend, T. A., Wrana, J. L., Davis, G. E., Barnett, J. V. (2008). Transforming Growth Factor-{beta}-stimulated Endocardial Cell Transformation Is Dependent on Par6c Regulation of RhoA. J. Biol. Chem. 283: 13834-13841 [Abstract] [Full Text]  
• Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al-Shamma, H., Smith, B., Chalmers, D., Behan, D. (2008). Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization. J. Pharmacol. Exp. Ther. 325: 577-587 [Abstract] [Full Text]  
• Abel, E. D., Litwin, S. E., Sweeney, G. (2008). Cardiac Remodeling in Obesity. Physiol. Rev. 88: 389-419 [Abstract] [Full Text]  
• Bhattacharyya, S., Constantin, C., Davar, J., Mikhailidis, D. (2008). Longitudinal Effects of Fenfluramine--Phentermine Use. ANGIOLOGY 58: 772-773  
• Padera, R. F. Jr., Schoen, F. J. (2008). Pathology of Cardiac Surgery. Card Surg Adult 3: 111-178 [Full Text]  
• Bhattacharyya, S., Davar, J., Dreyfus, G., Caplin, M. E. (2007). Carcinoid Heart Disease. Circulation 116: 2860-2865 [Full Text]  
• Barnett, A. H (2007). Review: Pharmacotherapy as part of a weight management programme: a UK perspective. British Journal of Diabetes & Vascular Disease 7: 268-277 [Abstract]  
• Sookoian, S., Pirola, C. J. (2007). Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications. Therapeutic Advances in Cardiovascular Disease 1: 37-47 [Abstract]  
• Huizinga, M. M. (2007). Weight-Loss Pharmacotherapy: A Brief Review. Clin. Diabetes 25: 135-140 [Abstract] [Full Text]  
• Droogmans, S., Franken, P. R., Garbar, C., Weytjens, C., Cosyns, B., Lahoutte, T., Caveliers, V., Pipeleers-Marichal, M., Bossuyt, A., Schoors, D., Van Camp, G. (2007). In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 28: 2156-2162 [Abstract] [Full Text]  
• Borer, J. S., Pouleur, H., Abadie, E., Follath, F., Wittes, J., Pfeffer, M. A., Pitt, B., Zannad, F. (2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 28: 1904-1909 [Abstract] [Full Text]  
• Fleming, R. M., Boyd, L. B. (2007). The Longitudinal Effects of Fenfluramine-Phentermine Use. ANGIOLOGY 58: 353-359 [Abstract]  
• Ni, W., Fink, G. D., Watts, S. W. (2007). The 5-Hydroxytryptamine2A Receptor Is Involved in (+)-Norfenfluramine-Induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension. J. Pharmacol. Exp. Ther. 321: 485-491 [Abstract] [Full Text]  
• Greffe, G., Chalabreysse, L., Mouly-Bertin, C., Lantelme, P., Thivolet, F., Aulagner, G., Obadia, J.-F. (2007). Valvular Heart Disease Associated With Fenfluramine Detected 7 Years After Discontinuation of Treatment. Ann. Thorac. Surg. 83: 1541-1543 [Abstract] [Full Text]  
• Dewey, R. B. Jr, Reimold, S. C., O'Suilleabhain, P. E. (2007). Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonists in Parkinson Disease. Arch Neurol 64: 377-380 [Abstract] [Full Text]  
• Shimon, I., Benbassat, C., Hadani, M. (2007). Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156: 225-231 [Abstract] [Full Text]  
• Roth, B. L. (2007). Drugs and Valvular Heart Disease. NEJM 356: 6-9 [Full Text]  
• Yamamoto, M., Uesugi, T., Nakayama, T. (2006). Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study.. Neurology 67: 1225-1229 [Abstract] [Full Text]  
• Furberg, C. D., Levin, A. A., Gross, P. A., Shapiro, R. S., Strom, B. L. (2006). The FDA and drug safety: a proposal for sweeping changes.. Arch Intern Med 166: 1938-1942 [Abstract] [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B. (2006). ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1-e148 [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B. (2006). ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: 598-675 [Full Text]  
• Gillam, M. P., Molitch, M. E., Lombardi, G., Colao, A. (2006). Advances in the Treatment of Prolactinomas. Endocr. Rev. 27: 485-534 [Abstract] [Full Text]  
• Zolkowska, D., Rothman, R. B., Baumann, M. H. (2006). Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease. J. Pharmacol. Exp. Ther. 318: 604-610 [Abstract] [Full Text]  
• Kelly, C. R., Sharif, N. A. (2006). Pharmacological Evidence for a Functional Serotonin-2B Receptor in a Human Uterine Smooth Muscle Cell Line. J. Pharmacol. Exp. Ther. 317: 1254-1261 [Abstract] [Full Text]  
• DuBose, T. J. (2006). Are You Being Cited for Your Good Work?. Journal of Diagnostic Medical Sonography 22: 159-160  
• Kaplan, R M, Spring, B, Davidson, K (2006). APA, NAMI, NMHA, and evidence-based behavioural medicine: a comment.. Evid. Based Ment. Health 9: 32-34 [Full Text]  
• Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., Eckel, R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss.. Arterioscler. Thromb. Vasc. Bio. 26: 968-976 [Abstract] [Full Text]  
• Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., Eckel, R. H. (2006). Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113: 898-918 [Abstract] [Full Text]  
• Lai, V., Smith, A., Thorburn, D., Raman, V S (2006). Severe hepatic injury and adulterated Chinese medicines.. BMJ 332: 304-305 [Full Text]  
• Hillebrand, J J G, Heinsbroek, A C M, Kas, M J H, Adan, R A H (2006). The appetite suppressant d-fenfluramine reduces water intake, but not food intake, in activity-based anorexia. J Mol Endocrinol 36: 153-162 [Abstract] [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]  
• Levy, R. J. (2006). Serotonin Transporter Mechanisms and Cardiac Disease. Circulation 113: 2-4 [Full Text]  
• Lynch, M. J., Burns, R. G., Holcomb, J. E. (2005). Food for Thought: An Investigation of Food and Drug Administration Reporting Practices, 1995-1999. Criminal Justice Review 30: 293-311 [Abstract]  
• Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., Stunkard, A. J. (2005). Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. NEJM 353: 2111-2120 [Abstract] [Full Text]  
• Pinero, A., Marcos-Alberca, P., Fortes, J. (2005). Cabergoline-related severe restrictive mitral regurgitation.. NEJM 353: 1976-1977 [Full Text]  
• Sharma, A. M. (2005). Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system. Eur Heart J Suppl 7: L39-L43 [Abstract] [Full Text]  
• Miller, K. J. (2005). SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY. Mol. Interv. 5: 282-291 [Abstract] [Full Text]  
• Roberts, R. (2005). Another Chromosomal Locus for Mitral Valve Prolapse: Close but No Cigar. Circulation 112: 1924-1926 [Full Text]  
• Colman, E. (2005). Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants. ANN INTERN MED 143: 380-385 [Abstract] [Full Text]  
• Hong, Z., Smith, A. J., Archer, S. L., Wu, X.-C., Nelson, D. P., Peterson, D., Johnson, G., Weir, E. K. (2005). Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction. Circulation 112: 1494-1499 [Abstract] [Full Text]  
• Ni, W., Wilhelm, C. S., Bader, M., Murphy, D. L., Lookingland, K., Watts, S. W. (2005). (+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter. J. Pharmacol. Exp. Ther. 314: 953-960 [Abstract] [Full Text]  
• Tintner, R., Manian, P., Gauthier, P., Jankovic, J. (2005). Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease. Arch Neurol 62: 1290-1295 [Abstract] [Full Text]  
• Setola, V., Dukat, M., Glennon, R. A., Roth, B. L. (2005). Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor. Mol. Pharmacol. 68: 20-33 [Abstract] [Full Text]  
• Elangbam, C. S., Lightfoot, R. M., Yoon, L. W., Creech, D. R., Geske, R. S., Crumbley, C. W., Gates, L. D., Wall, H. G. (2005). 5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats. J. Histochem. Cytochem. 53: 671-677 [Abstract] [Full Text]  
• Gustafsson, B. I., Tommeras, K., Nordrum, I., Loennechen, J. P., Brunsvik, A., Solligard, E., Fossmark, R., Bakke, I., Syversen, U., Waldum, H. (2005). Long-Term Serotonin Administration Induces Heart Valve Disease in Rats. Circulation 111: 1517-1522 [Abstract] [Full Text]  
• LESSARD, E., GLICK, M., AHMED, S., SARIC, M. (2005). The patient with a heart murmur: Evaluation, assessment and dental considerations. Journal of the American Dental Association 136: 347-356 [Abstract] [Full Text]  
• Godoy-Matos, A., Carraro, L., Vieira, A., Oliveira, J., Guedes, E. P., Mattos, L., Rangel, C., Moreira, R. O., Coutinho, W., Appolinario, J. C. (2005). Treatment of Obese Adolescents with Sibutramine: A Randomized, Double-Blind, Controlled Study. J. Clin. Endocrinol. Metab. 90: 1460-1465 [Abstract] [Full Text]  
• Armbruster, B. N., Roth, B. L. (2005). Mining the Receptorome. J. Biol. Chem. 280: 5129-5132 [Full Text]  
• Czoty, P. W., Ramanathan, C. R., Mutschler, N. H., Makriyannis, A., Bergman, J. (2004). Drug Discrimination in Methamphetamine-Trained Monkeys: Effects of Monoamine Transporter Inhibitors. J. Pharmacol. Exp. Ther. 311: 720-727 [Abstract] [Full Text]  
• Kotloff, K. L., Corretti, M., Palmer, K., Campbell, J. D., Reddish, M. A., Hu, M. C., Wasserman, S. S., Dale, J. B. (2004). Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults: Phase 1 Trial. JAMA 292: 709-715 [Abstract] [Full Text]  
• Baseman, D. G., O'Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., Dewey, R. B. Jr (2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63: 301-304 [Abstract] [Full Text]  
• Ni, W., Li, M. W., Thakali, K., Fink, G. D., Watts, S. W. (2004). The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive. J. Pharmacol. Exp. Ther. 309: 845-852 [Abstract] [Full Text]  
• Woo, K. S., Chook, P., Yu, C. W., Sung, R. Y.T., Qiao, M., Leung, S. S.F., Lam, C. W.K., Metreweli, C., Celermajer, D. S. (2004). Effects of Diet and Exercise on Obesity-Related Vascular Dysfunction in Children. Circulation 109: 1981-1986 [Abstract] [Full Text]  
• Murphy, D. L., Lerner, A., Rudnick, G., Lesch, K.-P. (2004). Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics. Mol. Interv. 4: 109-123 [Abstract] [Full Text]  
• Hong, Z., Olschewski, A., Reeve, H. L., Nelson, D. P., Hong, F., Weir, E. K. (2004). Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L531-L538 [Abstract] [Full Text]  
• Rahimtoola, S. H. (2004). The year in valvular heart disease. J Am Coll Cardiol 43: 491-504 [Full Text]  
• Roberts, S. B, Krupa Das, S., Saltzman, E. (2004). Energy expenditure in obesity. Am. J. Clin. Nutr. 79: 181-182 [Full Text]  
• Dubose, T. J., Ludwig, R. (2003). Crystallography and the Gene Helix Discovery: An Interdisciplinary Educational Project. Journal of Diagnostic Medical Sonography 19: 340-346 [Abstract]  
• Van Camp, G., Flamez, A., Cosyns, B., Goldstein, J., Perdaens, C., Schoors, D. (2003). Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 61: 859-861 [Abstract] [Full Text]  
• Adachi, M., Saito, H., Kobayashi, H., Horie, Y., Kato, S., Yoshioka, M., Ishii, H. (2003). Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido. ANN INTERN MED 139: 488-492 [Abstract] [Full Text]  
• Weigle, D. S. (2003). Pharmacological Therapy of Obesity: Past, Present, and Future. J. Clin. Endocrinol. Metab. 88: 2462-2469 [Full Text]  
• Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., Roth, B. L. (2003). 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Mol. Pharmacol. 63: 1223-1229 [Abstract] [Full Text]  
• Unger, P., Nortier, J., Muniz Martinez, M.-C., Plein, D., Vandenbossche, J.-L., Vereerstraeten, P., Vanherweghem, J.-L. (2003). High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy. Nephrol Dial Transplant 18: 906-910 [Abstract] [Full Text]  
• Racette, S. B, Deusinger, S. S, Deusinger, R. H (2003). Obesity: Overview of Prevalence, Etiology, and Treatment. ptjournal 83: 276-288 [Full Text]  
• Studdert, D. M., Mello, M. M., Brennan, T. A. (2003). Medical Monitoring for Pharmaceutical Injuries: Tort Law for the Public's Health?. JAMA 289: 889-894 [Abstract] [Full Text]  
• Desai, N. D., Christakis, G. T. (2003). Stented Mechanical/Bioprosthetic Aortic Valve Replacement. Card Surg Adult 2: 825-856 [Full Text]  
• Corns, C, Metcalfe, K (2002). Risks associated with herbal slimming remedies. The Journal of the Royal Society for the Promotion of Health 122: 213-219 [Abstract]  
• Jian, B., Xu, J., Connolly, J., Savani, R. C., Narula, N., Liang, B., Levy, R. J. (2002). Serotonin Mechanisms in Heart Valve Disease I: Serotonin-Induced Up-Regulation of Transforming Growth Factor-{beta}1 via G-Protein Signal Transduction in Aortic Valve Interstitial Cells. Am. J. Pathol. 161: 2111-2121 [Abstract] [Full Text]  
• Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., Rosenzweig-Lipson, S., McGonigle, P., Levy, R. J., Liang, B. (2002). Serotonin Mechanisms in Heart Valve Disease II: The 5-HT2 Receptor and Its Signaling Pathway in Aortic Valve Interstitial Cells. Am. J. Pathol. 161: 2209-2218 [Abstract] [Full Text]  
• Humbert, M., Deng, Z., Simonneau, G., Barst, R.J., Sitbon, O., Wolf, M., Cuervo, N., Moore, K.J., Hodge, S.E., Knowles, J.A., Morse, J.H. (2002). BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20: 518-523 [Abstract] [Full Text]  
• Califf, R. M., DeMets, D. L. (2002). Principles From Clinical Trials Relevant to Clinical Practice: Part I. Circulation 106: 1015-1021 [Full Text]  
• Heisler, L. K., Cowley, M. A., Tecott, L. H., Fan, W., Low, M. J., Smart, J. L., Rubinstein, M., Tatro, J. B., Marcus, J. N., Holstege, H., Lee, C. E., Cone, R. D., Elmquist, J. K. (2002). Activation of Central Melanocortin Pathways by Fenfluramine. Science 297: 609-611 [Abstract] [Full Text]  
• Mcmillan, E, Martin, W L, Waugh, J, Rushton, I, Lewis, M, Clutton-Brock, T, Townend, J N, Kilby, M D, Gordon, C (2002). Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome. Lupus 11: 392-398 [Abstract]  
• Elangbam, C. S., Colman, K. A., Lightfoot, R. M., Tyler, R. D., Wall, H. G. (2002). Endocardial Myxomatous Change in Harlan Sprague-Dawley Rats (Hsd:S--D) and CD-1 Mice: Its Microscopic Resemblance to Drug-Induced Valvulopathy in Humans. Toxicol Pathol 30: 483-491 [Abstract]  
• Furberg, C. D (2002). To whom do the research findings apply?. Heart 87: 570-574 [Full Text]  
• Rothman, R. B. (2002). Anorexogen-Related Cardiac Valvulopathy. ANN INTERN MED 136: 779-779 [Full Text]  
• Kearns, P. (2002). Are There Benefits From Long-term Pharmacotherapy of Obesity?. Arch Intern Med 162: 1070-1070 [Full Text]  
• Ghali, W. A., Cornuz, J., McAlister, F. A., Wasserfallen, J.-B., Devereaux, P.J., Naylor, C. D. (2002). Accelerated publication versus usual publication in 2 leading medical journals. CMAJ 166: 1137-1143 [Abstract] [Full Text]  
• Kassirer, J. P. (2002). A medical early warning system. CMAJ 166: 1151-1152 [Full Text]  
• Yanovski, S. Z., Yanovski, J. A. (2002). Obesity. NEJM 346: 591-602 [Full Text]  
• Ray, J. G. (2002). Evidence in Upheaval: Incorporating Observational Data Into Clinical Practice. Arch Intern Med 162: 249-254 [Full Text]  
• Tomita, T., Zhao, Q. (2002). Autopsy Findings of Heart and Lungs in a Patient With Primary Pulmonary Hypertension Associated With Use of Fenfluramine and Phentermine. Chest 121: 649-652 [Abstract] [Full Text]  
• Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., Purnell, J. Q., Wheeler, M. (2002). Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care 25: 148-198 [Full Text]  
• Ehrle, L. H. (2001). Digging In An Ethical Minefield. Health Aff (Millwood) 20: 302-303 [Full Text]  
• Caccitolo, J. A., Connolly, H. M., Rubenson, D. S., Orszulak, T. A., Schaff, H. V. (2001). Operation for anorexigen-associated valvular heart disease. J. Thorac. Cardiovasc. Surg. 122: 656-664 [Abstract] [Full Text]  
• Glazer, G. (2001). Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety. Arch Intern Med 161: 1814-1824 [Abstract] [Full Text]  
• Belohlavkova, S., Simak, J., Kokesova, A., Hnilickova, O., Hampl, V. (2001). Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J. Appl. Physiol. 91: 755-761 [Abstract] [Full Text]  
• Arterburn, D., Noel, P. H. (2001). Extracts from ""Clinical Evidence"": Obesity. BMJ 322: 1406-1409 [Full Text]  
• Al Suwaidi, J., Higano, S. T., Holmes, D. R. Jr., Lennon, R., Lerman, A. (2001). Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37: 1523-1528 [Abstract] [Full Text]  
• Carr, M. E. Jr, Carr, S. L., Martin, E. J., Johnson, B. A. (2001). Rapid Clot Formation and Abnormal Fibrin Structure in a Symptomatic Patient Taking Fenfluramine: A Case Report. ANGIOLOGY 52: 361-366 [Abstract]  
• Eddahibi, S., Adnot, S., Frisdal, E., Levame, M., Hamon, M., Raffestin, B. (2001). Dexfenfluramine-Associated Changes in 5-Hydroxytryptamine Transporter Expression and Development of Hypoxic Pulmonary Hypertension in Rats. J. Pharmacol. Exp. Ther. 297: 148-154 [Abstract] [Full Text]  
• Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Prus-Wisniewski, R., Steinberg, C. (2001). Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial. Arch Intern Med 161: 218-227 [Abstract] [Full Text]  
• Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., Roth, B. L. (2000). Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. Circulation 102: 2836-2841 [Abstract] [Full Text]  
• Burger, A. J. (2000). Reply. J Am Coll Cardiol 36: 1435-1436 [Full Text]